title: [A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1].
abstract: Pancreatic acinar cell carcinoma is rare, and its incidence is less than 1% of all the malignant pancreatic tumors. Little is reported on effectiveness of chemotherapy. We report a 64-year-old male patient with pancreatic acinar cell carcinoma and a giant metastatic liver tumor, which responded to combination chemotherapy with gemcitabine(GEM)and peroral S-1 administration. The patient had upper abdominal pain and hypervascular tumors in liver(15 cm in diameter)and pancreas tail (3 cm in diameter), which were detected by an enhanced abdominal computed tomography(CT)scan, and was admitted for further examination. Abdominal angiography, FDG-positron emission tomography(PET), and liver tumor biopsy led to a diagnosis of pancreatic acinar cell carcinoma in the pancreas tail with liver metastasis. The patient was then treated with combination chemotherapy, which consisted of intravenous infusion of GEM and peroral administration of S-1, and the metastatic liver tumor was markedly reduced(partial response in RECIST). Although the prognosis of patients with unresectable pancreatic acinar cell cancers is generally unfavorable, it is suggested that the GEM/S- 1 combination chemotherapy is effective for these patients' treatment.
authors.affiliation: Third Dept. of Internal Medicine, Toyama University Hospital.
authors.forename: Toshinori
authors.initials: T
authors.lastname: Nishimizu
authors.forename: Masami
authors.initials: M
authors.lastname: Minemura
authors.forename: Shinya
authors.initials: S
authors.lastname: Kajiura
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Tokimitsu
authors.forename: Yuko
authors.initials: Y
authors.lastname: Itaya
authors.forename: Hidemoto
authors.initials: H
authors.lastname: Yamawaki
authors.forename: Kengo
authors.initials: K
authors.lastname: Kawai
authors.forename: Kazuto
authors.initials: K
authors.lastname: Tajiri
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Ayumu
authors.initials: A
authors.lastname: Hosokawa
authors.forename: Terumi
authors.initials: T
authors.lastname: Takahara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yasumura
authors.forename: Shigeki
authors.initials: S
authors.lastname: Shimizu
authors.forename: Junya
authors.initials: J
authors.lastname: Fukuoka
authors.forename: Shin
authors.initials: S
authors.lastname: Ishizawa
authors.forename: Takuro
authors.initials: T
authors.lastname: Sawasaki
authors.forename: Akio
authors.initials: A
authors.lastname: Yanagisawa
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D018267:Carcinoma, Acinar Cell / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine